Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review.
- Author:
Shu-ning WEI
1
;
Hui WEI
;
Ying-chang MI
;
Bing-cheng LIU
;
Kai-qi LIU
;
Chun-lin ZHOU
;
Qing-hua LI
;
Jian-xiang WANG
Author Information
- Publication Type:Case Reports
- MeSH: Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Benzenesulfonates; administration & dosage; Female; Humans; Leukemia, Monocytic, Acute; drug therapy; genetics; Niacinamide; analogs & derivatives; Phenylurea Compounds; Pyridines; administration & dosage; fms-Like Tyrosine Kinase 3; genetics
- From: Chinese Journal of Hematology 2011;32(1):8-11
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the safety and efficacy of sorafenib in combination with chemotherapy for the treatment of FLT3 positive acute myeloid leukemia (AML), to highlight the impact of FLT3 mutations and targeting therapy on response of AML.
METHODSThe clinical and laboratory features and the treatment response, especially the safety profile of sorafenib in an acute monocytic leukemia patient with FLT-ITD were reported.
RESULTSThe patient achieved clinical and molecular CR after sorafenib was added to the second course of combination chemotherapy. The side effects of sorafenib were mild and tolerable.
CONCLUSIONThe patient responded well to the combination of sorafenib and standard chemotherapy of AML without significant adverse effects.
